BMC Cancer 2007, 7:189 http://www.biomedcentral.com/1471-2407/7/189 for Miss Diao Yong Shu, Miss Li Hong and Miss Huang Zong Qiong (Nursing department of West China hospital). References 1. Jemal A, Tiwari RC, Murray T: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8-29. 2. American Society of Clinical Oncology: Clinical practice guide- lines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997, 15:2996-3018. 3. Joan HS, David H, Chandra PB: Comparison of Four Chemother- apy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2002, 346:92-98. 4. Comella P, Filippelli G, De Cataldis G: Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gem- citabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III ran- domised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 2007, 18:324-330. 5. D'Addario G, Pintilie M, Leighl NB: Platinum-Based Versus Non- Platinum-Based Chemotherapy in Advanced Non-Small- Cell Lung Cancer: A Meta-Analysis of the Published Litera- ture. J Clin Oncol 2005, 23:2926-2936. 6. Auperin A, Pechoux CL, Pignon JP: Concomitant radio-chemo- therapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-anal- ysis of individual data from 1764 patients. Ann Oncol 2006, 17:473-483. 7. Schuette W, Nagel S, Blankenberg T: Phase III Study of Second- Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel. J Clin Oncol 2005, 23:8389-8395. 8. Pectasides D, Pectasides M, Farmakis D: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chem- otherapy in advanced non-small-cell lung cancer: a rand- omized phase II trial. Ann Oncol 2005, 16:294-299. 9. Keun-Hyok Cho , Young-Bong Song , Ik-Sung Choi : A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treat- ment in Advanced Non-Small Cell Lung Cancer. Jpn J Clin Oncol 2006, 36:50-54. 10. Weiss GJ, Rosell R, Fossella F: The impact of induction chemo- therapy on the outcome of second-line therapy with peme- trexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18:453-460. 11. Gervais R, Ducolone A, Breton JL: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005, 16:90-96. 12. Di Maio M, Perrone F, Chiodini P: Individual Patient Data Meta- Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2007, 25:1377-1382. 13. Dörthe MK, Robins HI, Martina S: Role of Tumor Necrosis Fac- tor α in Hyperthermia-induced Apoptosis of Human Leuke- mia Cells. Cancer Res 1999, 59:3404-3410. 14. Engelhard R: Hyperthermia and drugs. Recent Results Cancer Res 1987, 104:136-203. 15. Hahn GM: Potential for therapy of drug and hyperthermia. Cancer Res 1979, 39:2264-2268. 16. Ellen LJ, James RO, Leonard RP: Randomized Trial of Hyperther- mia and Radiation for Superficial Tumors. J Clin Oncol 2005, 23:3079-3085. 17. Clemens MW, Sultan AR, Matthäus K: Response to Neoadjuvant Chemotherapy Combined With Regional Hyperthermia Predicts Long-Term Survival for Adult Patients With Retro- peritoneal and Visceral High-Risk Soft Tissue Sarcomas. J Clin Oncol 2002, 20:3156-3164. 18. Lindner LH, Schlemmer M, Hohenberger P: First interim report on the randomized EORTC 62961/ESHO-RHT 95 Inter- group Study (phase III) combined with regional hyperther- mia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults. ASCO Meet- ing Abstracts 2004, 22:9015. 19. Raymond NH, Vithal KG, Michael BL: Reduction of Tumor Bur- den in a Murine Osteosarcoma following Hyperthermia Combined with Cyclophosphamide. Cancer Res 1984, 44:1405-1408. 20. Kalapurakal JA, Mittal BB, Sathiaseelan V: Re-irradiation and exter- nal hyperthermia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report. Br J Radiol 2001, 74:745. 21. Vassilios EK, Costas ED, John RK: Liposomal Doxorubicin in Conjunction with Reirradiation and Local Hyperthermia Treatment in Recurrent Breast Cancer: A Phase I/II Trial. Clin Cancer Res 2002, 8:374. 22. Therasse P, Arbuck SG, Eisenhauer EA: New guidelines to evalu- ate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 23. National Cancer Institute [http://www.cancer.gov] 24. Shibata HR, MacClean LD: Blood flow to tumors. Progress Clin Can- cer 1966, 2:33-47. 25. Mohamed F, Stuart OA, Glehen O: Docetaxel and hyperthermia: factors that modify thermal enhancement. J Surg Oncol 2004, 88:14-20. 26. Yang HJ, Jiang GL, Fu XL: Radiotherapy and hyperthermia for NSCLC. ASCO Meeting Abstracts 2005, 23(16s):7289. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/7/189/pre pub Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 5 of 5 (page number not for citation purposes)